菲尔格拉斯蒂姆生物类似剂 (EP2006):对15年后批准证据的审查
Pere Gascón1, Nadia Harbeck2, Bernardo L Rapoport3
1Division of Medical Oncology, IDIBAPS, Hospital Clinic, Casanova 143, Barcelona 08036, Spain.
Critical reviews in oncology/hematology
|February 24, 2024
概括
生物类似的菲尔格拉斯蒂姆 (EP2006) 证明了与基准菲尔格拉斯蒂姆在化疗诱导的中性质衰竭和干细胞动员方面的有效性和安全性相似. 现实世界的证据证实了其在临床实践中的价值.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学 是一个学科.
- 血液学 血液学 血液学
背景情况:
- 菲尔格拉斯蒂姆是一种关键的治疗药物,用于治疗化疗引起的中性质衰竭和调动干细胞.
- EP2006是一种已批准的生物类似剂,用于参考filgrastim,自2009年以来已在全球范围内提供.
- 广泛的数据支持EP2006的结构,药理动力学和药理动力学相似性与参考filgrastim.
研究的目的:
- 审查和综合EP2006的临床前,临床和现实世界的证据.
- 为了评估EP2006的疗效,安全性和免疫性,与参考filgrastim相比.
- 评估EP2006在15年的市场存在期间的成本效益.
主要方法:
- 审查已公布的临床前和临床试验数据支持EP2006的批准.
- 对评估EP2006在临床实践中的真实世界证据研究的分析.
- 编制EP2006的成本效益数据.
主要成果:
- 临床前和临床数据证实了EP2006在多个领域与参考菲尔格拉斯蒂姆的生物相似性.
- 现实世界的研究证实了对减轻中性质衰竭和干细胞调动的同等有效性和安全性.
- 成本效益数据显示,EP2006的经济概况有利.
结论:
- EP2006是一种成熟的生物仿制药,其有效性和安全性已被证明与参考filgrastim相美.
- 现实世界的数据始终支持EP2006.的可互换性和临床实用性.
- EP2006提供了一种有价值的治疗选择,具有经过证明的成本效益.
相关概念视频
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:23Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...